Notice on Convening the 2025 Annual General Meeting
Filed with SSE · · 8 pages · Chinese
Gan & Lee Pharmaceuticals Co., Ltd. on 6ix
Earlier from Gan & Lee Pharmaceuticals
- Announcement on Obtaining Notice of Approval for Drug Clinical Trial
- Announcement on Completion of Administration of the First Subject in Phase III Clinical Trial of GZR33 Injection
- Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
- Announcement on Obtaining Drug Registration Approval by Wholly-owned Subsidiary
- Announcement on Completion of Administration of the First Subject in Phase I Clinical Trial of GLR2037 Tablets
Later from Gan & Lee Pharmaceuticals
- Announcement on Completion of Administration of the First Subject in Phase III Clinical Trial of New Indication of Bofanglutide (GZR18) Injection
- Announcement on Obtaining of European Commission Marketing Authorization for Aspart Injection
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Obtaining of European Commission Marketing Authorization for Insulin Lispro Injection
- Announcement on Implementation of Dividend Distribution for 2025
Follow Gan & Lee Pharmaceuticals into a list and get an email when it puts out news.
Follow Gan & Lee Pharmaceuticals